Building and Sustaining Strategic Relationships – Interview with Samir Shah

Relationships form the basis of any successful partnership. Trust and transparency are but two of the many factors that attribute to a strong and stable relationships. While it is easy to form such relationships, it is an upheaval task that requires consistency, diligence and sheer determination to maintain them. Sometime back, Samir Shah, Chief Operating Officer, PRA Health Sciences joined …

Today and tomorrow’s world – not-for-profits join with industry to develop drugs

I’ve had several conversations with pharmaceutical industry experts in the last few days. There seems to be increasing interest from sponsors marrying up with research charities. I thought that I would share some examples with you. Cancer Research UK developed Clinical Development Partnerships (CDP) meaning that de-prioritised agents can be given a second chance. The initiative also opens the door …

Keynote: New Pharma Partnering & Investment Opportunities

We’re at the final stretch of the conference with the remaining keynote session, “New Pharma Partnering & Investment Opportunities with Ajith Kamath, Wheaton Little and Younghwa Kim. Ajith Kamath, Senior Director and Head, Strategic Research Partnerships, Pfizer India spoke about the latest opportunities for strategic research partnerships in drug discovery by presenting drug discovery collaboration models at Pfizer. In an …

Download: eBook ‘Successful strategic pharmacovigilance partnerships’

Partnerships play an integral part right across the pharma industry. Now more than ever before developing long term strategic partnerships in PV is proving to be vital. Several high-profile safety issues, regulatory warnings and negative media coverage have forever changed pharmacovigilance as we know it today. The best relationships between sponsors and contractors are those that are well defined from …

Download: Optimising Clinical Development & Speeding Patient Access to Orphan Drugs

In preparation for the 2014 World Orphan Drug Congress in Geneva, we have collated a number of interviews from some of the leading orphan drug developers. The industry-at-large are investing more and more resources into rare disease research, and numerous companies are now deploying the scientific, regulatory and strategic expertise to progressed an orphan drug to market. With over 7000 …

Download presentation- Evolving the Orphan Innovation Model: Partnership at the Heart of Sustainable Orphan Development

In November 2012 over 250 delegates participated in the 3rd Annual World Orphan Drug Congress Europe. This event covers strategies and opportunities from Clinical Development and R&D, Market Access, Pricing & Reimbursement , Corporate Development and Drug Repositioning & Indication Expansion. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Geoffrey McDonough, President …

Download: Top tips for orphan drug clinical development, market access and rare disease partnerships

In the second of our eBook series about the rare disease industry, we have collated a number of interviews from some of the leading orphan drug developers. The industry-at-large are investing more and more resources into rare disease research, however only a handful of organisations have the scientific, regulatory and strategic expertise to have progressed an orphan drug to market. …

Top 3 partnerships between Big Pharma and Academia

As the drug discovery business goes through difficult times, drug candidates can't seem to move through the pharmaceutical industry process fast enough. As well, entrepreneurs are struggling to get the funding they need to carry through their ideas to fruition.  Can partnerships between big pharma and academia help?  With the many recent cases of new alliances and partnerships in the …

A meeting of Orphan Drug pioneers & rare disease experts to drive innovation

    In a previous post, I outlined the changes being made to the 3rd Annual World Orphan Drug Congress and the fact that 3 focused tracks will be taking place simultaneously that focus on: Clinical Development and R&D Market Access, Pricing & Reimbursement Corporate Development & Partnerships More dedicated content means more high level and pioneering speakers to shape …